Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 26;10(1):00935-2023.
doi: 10.1183/23120541.00935-2023. eCollection 2024 Jan.

Articular manifestations related to anti-interleukin-5 therapies in severe asthma: a case series

Clairelyne Dupin  1   2   3 , Solène Valéry  1   3 , Laurent Guilleminault  2   4   5 , Gilles Devouassoux  2   6 , Marine Merveilleau  6 , Maud Russier  7 , Gisèle Mourin  8 , Johana Pradelli  9 , Philippe Bonniaud  10 , Mathilde Le Brun  1   2 , Esther Ebstein  11 , Pierre-Antoine Juge  11 , Agnès Lillo-Lelouet  12 , Camille Taillé  1   2
Affiliations

Articular manifestations related to anti-interleukin-5 therapies in severe asthma: a case series

Clairelyne Dupin et al. ERJ Open Res. .

Abstract

Articular manifestations should be screened before and during anti-IL-5/5R biologic treatment in severe asthma. Rigorous multidisciplinary team discussion should be carried out to assess the risk-benefit balance of withholding effective treatment. https://bit.ly/3vfPn4k.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: C. Dupin reports consulting fees from AstraZeneca, Sanofi and GSK; lecture honoraria from AstraZeneca, GSK, Sanofi, Novartis, Chiesi, OPA Pratique, Pneumoscoop and La Lettre du Pneumologue; and travel support from AstraZeneca, Sanofi, Novartis, Chiesi and GSK; all outside the submitted work. Conflict of interest: L. Guilleminault reports grants from AstraZeneca; consulting fees from Bayer, MSD, AstraZeneca, GSK, Novartis, Sanofi and Chiesi; lecture honoraria from MSD, AstraZeneca, GSK, Novartis, Sanofi and Chiesi; payment for expert testimony from Bayer, MSD and Sanofi; and travel support from MSD, AstraZeneca, GSK, Novartis and Sanofi; all outside the submitted work. Conflict of interest: G. Devouassoux reports lecture or consulting fees from GSK, Menarini, ALK, AstraZeneca, Novartis, Chiesi and Sanofi; payment for expert testimony from GSK, AstraZeneca, Sanofi and Chiesi; and travel support from AstraZeneca, GSK, Sanofi, Novartis, Chiesi; all outside the submitted work. Conflict of interest: M. Le Brun reports grants from GSK, AstenSante and Novartis; lecture honoraria from GSK and La Revue du Praticien; and travel support from Asten Santé and Novartis; all outside the submitted work. Conflict of interest: G. Mourin reports lecture honoraria from AstraZeneca and GSK; and travel support from AstraZeneca, Sanofi, Menarini and GSK; all outside the submitted work. Conflict of interest: P. Bonniaud reports grants from AstraZeneca; lecture honoraria from Sanofi and AstraZeneca; travel support from AstraZeneca, Novartis and Sanofi; advisory board participation from AstraZeneca, Novartis, Sanofi and GSK; all outside the submitted work. Conflict of interest: E. Ebstein reports consulting fees from Abbvie, Novartis and BMS; lecture honoraria from UCB and Galapagos; and travel support from UCB and Novartis; all outside the submitted work. Conflict of interest: C. Taillé reports grants from GSK; consulting fees from AstraZeneca, GSK and Sanofi; lecture honoraria from AstraZeneca, GSK, Sanofi, Novartis, Stallergenes and Chiesi; and travel support from AstraZeneca and GSK; all outside the submitted work. Conflict of interest: S. Valéry, M. Merveilleau, M. Russier, J. Pradelli, P-A. Juge all have nothing to disclose.

References

    1. Pavord ID, Korn S, Howarth P, et al. . Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651–659. doi:10.1016/S0140-6736(12)60988-X - DOI - PubMed
    1. Bleecker ER, FitzGerald JM, Chanez P, et al. . Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388: 2115–2127. doi:10.1016/S0140-6736(16)31324-1 - DOI - PubMed
    1. Taillé C, Chanez P, Devouassoux G, et al. . Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Eur Respir J 2020; 55: 1902345. doi:10.1183/13993003.02345-2019 - DOI - PMC - PubMed
    1. Kawabata H, Satoh M, Yatera K. Development of rheumatoid arthritis during anti-interleukin-5 therapy in a patient with refractory chronic eosinophilic pneumonia. J Asthma Allergy 2021; 14: 1425–1430. doi:10.2147/JAA.S342993 - DOI - PMC - PubMed
    1. Andreev D, Liu M, Kachler K, et al. . Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis. Ann Rheum Dis 2021; 80: 451–468. doi:10.1136/annrheumdis-2020-218902 - DOI - PubMed

LinkOut - more resources